globenewswire

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.

WASHINGTON, D.C., June 30, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of banking and payments expert Christopher Allen as a Senior Managing Director in the Financial Services practice within the Forensic and Litigation Consulting segment.

LONDON, June 30, 2025 (GLOBE NEWSWIRE) -- Diginex Limited (“Diginex” or the “Company”) (NASDAQ: DGNX), a leading provider of Sustainability RegTech solutions, today announced additional government funding support for its innovative AI-powered compliance solutions. Diginex’s AI-powered compliance solutions will continue to focus on helping companies comply with sustainability disclosure requirements set by the International Sustainability Standards Board (ISSB) and International Financial Reporting Standards (IFRS) and now with the enhanced scope of AI-powered compliance solutions will additionally offer features including multi-variant drafts, risk reduction through automation, future-proofing against new regulations as well as enhanced scalability for users of the Company’s ESG SaaS reporting product, diginexESG. Diginex’s expanded AI features will streamline ESG reporting processes, thereby empowering businesses and financial institutions to meet regulatory requirements efficiently while driving transparency in corporate social responsibility and climate action, and will be jointly developed with a leading financial institution through a co-creation collaboration model promoting commercialisation and wider adoption.

On 5 February 2025, Pandora announced a new share buyback programme, cf. Company announcement no. 923. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
                                                                                                                                                      
The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes.

BROOKFIELD, NEWS, June 30, 2025 (GLOBE NEWSWIRE) -- Brookfield Infrastructure Partners will hold its second quarter 2025 conference call and webcast on Thursday, July 31, 2025 at 9:00 a.m. (ET).

Master market access for medical device software with our expert-led course. Navigate international regulations, understand reimbursement pathways, and enhance commercial success globally. Gain insights with real-life examples and earn CPD certification. Join now to ensure market entry success!

KINGSTOWN, Saint Vincent and the Grenadines, June 30, 2025 (GLOBE NEWSWIRE) -- Amid a growing wave of phishing scams targeting the crypto industry, Millionero, a trusted spot and perpetual exchange, is taking a stand. The company is urging all users to stay vigilant and follow key safety measures as scammers impersonate brands, executives, and platforms with increasing sophistication.

Albion Technology & General VCT PLC

BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx*—its digital pathology image management system—for use in primary diagnosis in clinical settings. Building on the initial 510(k) clearance for AISight Dx(Novo) in 2022, this latest milestone underscores the platform’s continuous innovation and PathAI’s commitment to delivering enhanced capabilities as the product evolves.

Heineken Holding N.V. reports transactions under its current share buyback programme

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta’s top executives with violations of the Securities Exchange Act of 1934.